Status:

UNKNOWN

Tolerance of Anti-Cancer Therapy in the Elderly

Lead Sponsor:

The Leeds Teaching Hospitals NHS Trust

Conditions:

Frailty

Chemotherapeutic Toxicity

Eligibility:

All Genders

65+ years

Brief Summary

This is a multicentre observational study evaluating frailty and tolerance of chemotherapy in the elderly.

Detailed Description

This is a multicentre observational study evaluating frailty and tolerance of chemotherapy in the elderly. The number of people with cancer over the age of 65 years is increasing and more older patie...

Eligibility Criteria

Inclusion

  • Age \>65years
  • About to start first line chemotherapy for a solid tumour based malignancy
  • Chemotherapy given for any intent eg. adjuvant or palliative
  • Estimated survival of \>3months
  • Able to comprehend and complete questionnaire.

Exclusion

  • Medical or psychiatric condition impairing ability to consent
  • Participant is enrolled in another clinical trial
  • Prior chemotherapy for any indication
  • Receiving concurrent radiotherapy (RT) or immunotherapy (IT)
  • Unable to provide informed consent

Key Trial Info

Start Date :

November 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2023

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT05251922

Start Date

November 1 2020

End Date

June 1 2023

Last Update

February 23 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Leeds NHS Teaching Hospitals

Leeds, United Kingdom

Tolerance of Anti-Cancer Therapy in the Elderly | DecenTrialz